<DOC>
	<DOCNO>NCT01110603</DOCNO>
	<brief_summary>This study find dose limit toxicity ( DLTs ) , maximum tolerate dose ( MTD ) , recommend Phase 2 dose ( RPTD ) MK4827 administer combination standard dose carboplatin , carboplatin/paclitaxel , carboplatin/liposomal doxorubicin treatment advance solid cancer adult .</brief_summary>
	<brief_title>A Study MK-4827 Combination With Standard Chemotherapy Participants With Advanced Solid Tumors ( MK-4827-008 AM1 )</brief_title>
	<detailed_description>The decision discontinue new enrollment relate concern safety profile product .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Niraparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Participant locally advance metastatic solid tumor carboplatin , carboplatin/paclitaxel , carboplatin/liposomal doxorubicin standard care . Participant performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Participant chemotherapy , radiotherapy , biological therapy within 4 week prior enter study . Participant two prior line chemotherapy . Participant known central nervous system metastases primary central nervous system tumor . Participant pregnant breastfeeding expect conceive timeframe study . Participant known human immunodeficiency virus ( HIV ) positive . Participant history Hepatitis B C. Participant symptomatic pleural effusion . Participant leave ventricular ejection fraction ( LVEF ) institutional norm , prior exposure doxorubicin eligible MK4827 + carboplatin/liposomal doxorubicin study arm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>